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E6APHuman papillomavirus (HPV) E6 oncoproteins target numerous cellular proteins for ubiquitin-mediated
degradation. In the case of p53 this is mediated by the E6AP ubiquitin ligase. However, there are conﬂicting
reports concerning how central E6AP is to the global function of the HPV-16 and HPV-18 E6 oncoproteins. To
investigate this further we have analysed the effects of E6AP removal upon the stability of endogenously
expressed E6 protein. We show that when E6AP is silenced in HPV-positive cells, E6 protein levels are
dramatically decreased in a proteasome-dependent manner. Further, we show that when E6AP is depleted in
HeLa cells, E6 has a greatly decreased half-life. In addition, overexpression of E6AP stabilises ectopically
expressed HPV-16 and HPV-18 E6 in a manner that is independent of its ubiquitin ligase activity. These
results demonstrate that the stability of HPV E6 is critically dependent upon the presence of E6AP.
© 2009 Elsevier Inc. All rights reserved.Introduction
The oncogenic activity of high-risk HPV is caused by cooperation of
two viral oncoproteins, E6 and E7. They target cellular proteins
involved in the regulation of apoptosis and cell cycle, causing
immortalization and, eventually, cellular transformation (Mantovani
and Banks, 2001; Munger et al., 2001). One of the most important
targets of E6 is the p53 tumour suppressor, which it targets for
proteasome mediated degradation (for review Thomas et al., 1999).
This activity is dependent upon the recruitment of a 100 kDa cellular
ubiquitin ligase, E6AP, to the complex, which then leads to p53 poly-
ubiquitination followed by proteasomal degradation (Huibregtse et
al., 1993; Scheffner et al., 1993).
Many studies have shown that in the absence of E6AP, E6 is no
longer able to target p53 for degradation, and this leads to an increase
in p53 levels and activity (Beer-Romero et al., 1997; Hengstermann et
al., 2005; Talis et al., 1998). However, whether E6AP plays a central
role in other activities of E6 has been the subject of considerable
debate. Many in vivo analyses highlight the importance of E6AP for E6
mediated degradation of several cellular targets (Handa et al., 2007;
Kuballa et al., 2007), including the PDZ domain-containing substrates,
whilst other in vitro analyses seem to suggest that E6AP is not always
required (Grm and Banks, 2004). A number of recent studies have also
suggested that E6 can even target p53, as well as other substrates, in
an E6AP-independent fashion in vivo (Camus et al., 2007; Grm and
Banks, 2004; Massimi et al., 2008; Shai et al., 2007; Storrs and
Silverstein, 2007). Finally, an elegant series of studies has suggested
that the global transcriptional effects of E6 upon the cell are largely
dependent on the presence of E6AP (Kelley et al., 2005), suggesting,l rights reserved.indirectly, that all of E6's activities are mediated through its
association with E6AP.
Results
E6 protein stability is E6AP dependent in HeLa cells
Many of the above studies have involved either overexpression
systems or, in cases where endogenous E6 was analysed, under
conditions in which the level of E6 protein expression was not
determined. Therefore in order to further clarify the role of E6AP in
the function of E6, we ﬁrst investigated the levels of E6 expression
in HPV-positive cells in the presence and absence of E6AP. To do
this, HPV-18-containing HeLa cells were transfected with siRNAs
directed against either E6AP, HPV-18 E6 or Luciferase for compar-
ison, and the levels of both proteins were then analysed by western
blot analysis. The proteasome inhibitor CBZ was also added to the
cells 2.5 h prior to harvesting to determine whether changes in the
pattern of protein expression were proteasome-dependent. Cells
were harvested 72 h post-transfection, and the total cellular lysates
were subjected to western blot analysis using anti-E6AP, anti-
tubulin, and anti-18E6 antibodies. The results obtained are shown in
Fig. 1. As can be seen, the reduction of E6 levels by siRNA results in
a marked upregulation in the level of E6AP expression, and this is
consistent with previous observations showing that E6 induced the
auto-ubiquitination and degradation of E6AP (Kao et al., 2000).
Most strikingly however, ablation of E6AP expression also results in
a dramatic reduction in E6 protein, to levels that are even lower
than those obtained using the E6 siRNA. In addition, inclusion of the
proteasome inhibitor CBZ prior to harvest rescued the expression of
E6, indicating that its decreased level in the cell is proteasome
mediated. In order to reduce the possibility of off-target effects of
Fig. 1. HPVE6protein stability inHPV-positiveHeLa cells is E6AP dependent. HeLa cellswere
transfected with siRNA Luciferase, or siRNA E6AP, or siRNA 18E6/E7. After 72 h cells were
incubatedwith or without CBZ (Z-Leu-Leu-al/Sigma) for 2.5 h to block the proteasome, with
DMSO treatment as control. The cells were then harvested and the protein levels were
detected using western blotting with anti-E6AP antibody, anti-tubulin antibody to monitor
protein loading, and anti-18E6 antibody, followed by HRP-coupled anti-mouse antibody and
ECL detection. Note that the siRNA E6AP (SCBT) track is from the same experiment and
western blot and the arrows indicate the positions of the E6AP, tubulin, and E6 proteins.
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from another supplier (SCBT lane), and an identical reduction in the
level of E6 expression was obtained. These results demonstrate that
E6 steady state levels are strongly dependent upon the presence of
E6AP, and that when E6AP is not present E6 is down-regulated in a
proteasome-dependent manner.
E6AP silencing does not signiﬁcantly affect E6 RNA transcription
To further investigate the effects of E6AP ablation upon E6
expression levels, we proceeded to determine whether this was in any
way related to the level of E6 geneexpression. Todo this,HeLacellswere
transfected with siRNA Luciferase or siRNA E6AP. After 72 h the cells
were harvested and total RNA was extracted and processed with and
without Reverse Transcriptase. The cDNAs were then ampliﬁed using
HPV-18E6ﬂankingprimers and the results obtained are shown in Fig. 2.
It can be seen that the presence or absence of E6AP has minimal effect
upon the level of HPV-18 E6 gene expression, as determined by this
semi-quantitative assay. These results demonstrate that the decrease in
the levels of E6protein that is observedwhenE6AP isdepleted is not due
to any major changes in the levels of HPV gene expression, but rather is
mostly due to a decrease at the protein level.
E6AP regulates E6 protein turnover
Having shown that E6AP ablation reduces the steady state levels of
E6 we then wanted to analyse the effects upon E6 protein turnover.Fig. 2. E6 RNA transcripts are not affected by E6AP silencing. HeLa cells were transfected
with siRNA Luciferase or siRNA E6AP. After 72 h cells were harvested and total RNA was
extracted. Puriﬁed RNA was then annealed with random decamers and cDNAs
generated with Reverse Transcriptase; to control for plasmid DNA carry over, a parallel
set of random decamer-annealed samples was incubated without RT (−RT). The cDNAs
generated from the RT step, and their control samples were ampliﬁed using HPV-18 E6
ﬂanking oligos. Arrows indicate the position of full length E6, alternatively spliced E6⁎
(Schneider-Gadicke and Schwarz, 1986) and the GADPH loading control.Assays were performed as above in HeLa cells, using siRNA Luciferase as
a negative control and siRNA against E6AP. 48 h post-transfection the
cells were treated with Cycloheximide for different times in order to
determine whether E6AP had any effect on E6 protein half-life. The
levels of E6 protein were then assessed by western blot analysis using
the anti-18 E6monoclonal antibody and the results obtained are shown
in Fig. 3A, with the quantitation frommultiple assays shown in Figs. 3B
and C. As can be seen, when cells were treated with the control siRNA
the E6 protein levels remained relatively unchanged from time-point 0
to 60 minutes, and they started to decrease at the 120 minute time-
point, as one would expect from previous reports (Androphy et al.,
1987; Grossman et al., 1989). In contrast, when E6AP is depleted from
the cells theE6 levels showa signiﬁcantdecreaseby the30minute time-
point, and the protein is completely absent by the 120 minute time-
point. These results show that silencing E6AP in HPV-positive HeLa cells
results in a dramatic increase in E6 protein turnover.
We then reasoned that under conditions of E6 overexpression, co-
transfection of exogenous E6AP should also result in an increase in the
levels of E6 protein expression. To investigate this, HEK 293 cells were
transfected with HPV-16 and HPV-18 E6 expression plasmids,
together with FLAG-tagged wild type E6AP and a catalytically inactive
E6AP mutant, in order to determine whether E6AP enzymatic activity
was also required for E6 stabilisation. The expression levels of E6AP
and E6 were then determined by western blotting. The results, in
Fig. 4, show a number of interesting points. Firstly, HPV-16 E6 appears
to degrade E6AP more strongly than HPV-18 E6, and this is in part
dependent upon E6AP catalytic activity. These results are in agree-
ment with previous studies (Kao et al., 2000). Most importantly
however, both the wild type and mutant E6AP signiﬁcantly increase
the levels of both HPV-16 and HPV-18 E6 expression. These results
demonstrate that E6AP contributes directly to the increased stability
of HPV-16 and HPV-18 E6, and further, that this is independent of
E6AP's catalytic activity.
Discussion
Previous studies have shown that E6AP is critical for the ability of
E6 to target p53 for proteasome mediated degradation, which was
largely believed to be a consequence of E6AP's ubiquitin ligase
activity. However, there have been several reports that E6 can degrade
proteins, albeit weakly, in the absence of functional E6AP, suggesting
the existence of other routes by which E6 can degrade its substrate
proteins (Camus et al. 2007;Massimi et al., 2008). Most importantly, it
was also found (Kelley et al., 2005) that all the effects of E6 on cellular
gene expression were mediated by E6AP. At ﬁrst glance, these
different studies appear irreconcilable. However, the results of the
analysis presented here are perfectly consistent with all of the above
reports. Thus, in the absence of E6AP, E6 levels are very low and the
protein is rapidly degraded at the proteasome. Obviously, a by-
product of this would be an apparent central requirement for E6AP in
all of E6's biochemical activities, with loss of E6AP mimicking E6
ablation. However, in the light of the studies presented here, we can
now conclude that the actual biochemical functions of E6, whilst
needing E6AP for stability, are not necessarily E6AP-dependent with
respect to substrate targeting and degradation.
These results raise a number of other interesting points. Firstly, it
demonstrates that HPV-16 and HPV-18 E6 are regulated by the
proteasome independently of E6AP, suggesting that other ubiquitin
ligases may be involved in regulating E6 turnover. Whether these are
involved in E6-induced degradation of some of its substrates is also an
important question. These results also suggest that E6AP somehow
blocks E6 degradation; this might be through masking E6 sites of
ubiquitination or by altering E6 structure such that E6AP acts as a
molecular chaperone. However, degradation of any putative E6
ubiquitin ligase by E6AP seems unlikely, since catalytically inactive
E6AP is also capable of stabilising E6. This also suggests that this
Fig. 3. E6 protein turnover is regulated by E6AP. A. HeLa cells were transfected with siRNA Luciferase or siRNA E6AP. 48 h post-transfection and prior to harvesting cells were treated
with Cycloheximide for 5 different time points 0', 15', 30', 60' and 120'. Protein levels were detected using western blotting with anti-E6AP antibody, anti-tubulin antibody tomonitor
protein loading, and anti-18E6 antibody, followed by HRP-coupled anti-mouse antibody and ECL detection. Arrows indicate the positions of the E6AP, tubulin, and E6 proteins. The
collated results from 3 independent experiments to measure E6 protein turnover in cells treated with siRNA Luciferase and siRNA E6AP are shown in panels B and C respectively.
Band intensities were determined using the OptiQuant quantiﬁcation program. E6 levels normalized to 100% at time 0. Standard deviations are also shown.
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E6 degradation of p53 (Beer-Romero et al., 1997; Talis et al., 1998),
may alter E6 structure or inhibit ligase recruitment, rather than just
acting to destabilise E6. These studies also suggest that variations in
the levels of certain E6 substrate proteins, frequently observed in
cervical tumour tissues (Cavatorta et al., 2004; Cooper et al., 1993),
might actually be a reﬂection of alterations in E6AP levels or of the
ability of E6AP to bind E6. Future studies will now aim to elucidate
these aspects further and clarify how E6 mediates its degradation
functions in the presence and absence of E6AP.
Materials and methods
Cell culture
HeLa and HEK293 cells were grown in DMEM supplemented with
10% fetal bovine serum, penicillin–streptomycin (100 U/ml) and
glutamine (300 μg/ml).Fig. 4. Stabilisation of E6 by E6AP. HEK 293 cells were transfected with plasmids expressi
catalytically inactive mutant of E6AP (C→A) plus a LacZ expression plasmid. After 24 h the ce
HPV-16 and HPV-18 E6 were monitored using the respective anti-E6 monoclonal antibody. B
blots were developed using appropriate HRP conjugated secondary antibody and ECL detecPlasmids
Untagged HPV-18 E6 and HPV-16 E6 pCDNA-3 expression
plasmids have been described previously (Gardiol et al., 1999; Pim
et al., 1994), as have the wild type and mutant E6AP (C→A)
expression plasmids (Brimer et al., 2007).
Antibodies
The following antibodies were used: mouse monoclonal antibody
against E6AP (1:500/BD Transduction Labs), anti-tubulin antibody
(1:1000/Sigma Aldrich), mouse monoclonal anti-18E6 antibody
(1:1000/Arbor Vita Corporation [N-terminus #399]), mouse mono-
clonal anti-16E6 antibody (1:1000/Arbor Vita Corporation
[N-terminus #74 and C-terminus #813]), anti-FLAG monoclonal
antibody (1/1000/Sigma) and anti-LacZ antibody (1/5000/Promega).
Appropriate secondary antibodies conjugated to HRP were obtained
from DAKO (1:1000).ng HPV-16 and HPV-18 E6, together, as indicated, with FLAG-tagged wild type and a
lls were harvested and the levels of E6APweremonitored using anti-FLAG antibody, and
lots were stripped and re-probed for LacZ to control for transfection efﬁciency. Western
tion.
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HeLa cells were seeded on 6 cm dishes and transfected using
Lipofectamine 2000 (Invitrogen) with control siRNA against Lucifer-
ase (siLuc), or siRNA against HPV-18 E6/E7 sequences Dharmancon, or
siRNA against E6AP sequences (Dharmacon and Santa Cruz). 72 h
post-transfection cells were harvested and total cells extracts
analysed by western blotting.
Western blotting
Cells were lysed in SDS lysis buffer. The whole cells extracts were
analysed by SDS-PAGE and western blotting. For western blotting,
0.22 μm nitrocellulose membrane (Schleicher and Schuell) was used
andmembranes were blocked for 1 h at 37 °C in 10%milk/PBS followed
by the incubationwith the appropriate primary antibody diluted in 10%
milk/0.5% Tween 20 for 2 h. After severalwashingswith PBS 0.5% Tween
20, secondary antibodies conjugatedwithHRP (DAKO) in 10%milk/0.5%
Tween 20 were incubated for 1 h. Blots were developed using
Amersham ECL reagents according to the manufacturer's instructions.
Reverse Transcriptase (RT) RNA processing
Total RNA was extracted using the Tri reagent system (Sigma
Aldrich) according to the manufacturer's protocol. The puriﬁed RNA
was treated with RQ1 RNAse-free DNAse (Promega) according to the
manufacturer's protocol to remove any plasmid DNA carried over
during the RNA extraction. 2 μg of puriﬁed RNA was then annealed
with random decamers and cDNAs generated with Reverse Tran-
scriptase using a RETROScript Kit (Ambion) according to the
manufacturer's instructions. The cDNAs generated from the RT step,
and their control samples were ampliﬁed using HPV-18 E6 ﬂanking
oligos and Go-Taq Polymerase (Promega).
Half-life experiments
Prior to harvesting, cells were treated with Cycloheximide
(1:2000/Sigma Aldrich) for different periods of time, after which the
cells were harvested and subjected to western blot analysis.
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